Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Fig. 3

Proportion of participantsa,b with ≥ 50% (a, b) or ≥ 75% (c, d) reduction in MAMD. CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMD

Back to article page